Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
P2P Loan
Grow your wealth in fiat investment
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
U.S. stock CFD derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
2026 World Cup
Rewards

Sellas Life Sciences Surges 53%, ImmunityBio Gains 10% in June as Biotech ETF Climbs 17%

GateNews
Stocks
According to Stocktwits data, Sellas Life Sciences (SLS) surged 53% and ImmunityBio Inc. (IBRX) gained 10% in June, while the SPDR S&P Biotech ETF (XBI) climbed 17% for one of its strongest monthly performances since December 2023. Edison Investment Research highlighted continued opportunities in oncology across immuno-oncology, targeted therapies, and other cancer-treatment areas. For SLS, the Regal trial for GPS in acute myeloid leukemia (AML) has reached 78 of 80 events needed for final analysis. For IBRX, the FDA accepted an application seeking to expand Anktiva for bladder cancer, with a decision target date of January 6, 2027.
View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

3h ago
Hang Seng Index Rises 2.12% as Healthcare Sector Surges 8.9% in Morning Trade
6h ago
Hang Seng Index Opens Up 0.69% on June 29; Tech Stocks Rally With NetEase Up Over 4%
06-27 23:19
Nasdaq Biotechnology Index Closes Up 2.2%, Hits Fifth Consecutive Record High on June 26
06-26 23:16
Nasdaq Biotech Index Surges Over 2.2% on June 26, Hits Fifth Consecutive Record Close
06-26 16:28
Software Stocks Outperform Semiconductors as Fund Rotation Accelerates on June 27
In-Depth Analysis

SLS, MRNA, ABCL Stocks Hit 52-Week Highs on Clinical and Partnership Catalysts

Lucas Bennett4h ago

ServiceNow Rises Nearly 10% as Software Stocks Rebound on OpenAI IPO Delay Reports

Lucas Bennett4h ago

Sol Strategies Stock Rises 22% as Solana Treasury Model Draws Attention

Lucas Bennett06-28 02:37
Comment
0/400
No comments